Adverse events630

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 630

Type	Event	Organ system	Group	Affected	At risk	Events
other	Investigations, Other	Investigations	A: Daratumumab & Dexamethasone	20	33	106
other	Investigations, Other	Investigations	B: Daratumumab, Dexamethasone and Lenalidomide	8	12	51
other	Investigations, Other	Investigations	C: Daratumumab, Dexamethasone and Bortezomib	6	7	32
other	Blood lactate dehydrogenase increased	Investigations	A: Daratumumab & Dexamethasone	15	33	33
other	Blood lactate dehydrogenase increased	Investigations	B: Daratumumab, Dexamethasone and Lenalidomide	5	12	7
other	Blood lactate dehydrogenase increased	Investigations	C: Daratumumab, Dexamethasone and Bortezomib	4	7	11
other	Lymphocyte count decreased	Investigations	A: Daratumumab & Dexamethasone	6	33	14
other	Lymphocyte count decreased	Investigations	B: Daratumumab, Dexamethasone and Lenalidomide	5	12	13
other	Lymphocyte count decreased	Investigations	C: Daratumumab, Dexamethasone and Bortezomib	1	7	1
other	Neutrophil count decreased	Investigations	A: Daratumumab & Dexamethasone	5	33	10
other	Neutrophil count decreased	Investigations	B: Daratumumab, Dexamethasone and Lenalidomide	7	12	18
other	Neutrophil count decreased	Investigations	C: Daratumumab, Dexamethasone and Bortezomib	2	7	3
other	Alkaline phosphatase increased	Investigations	A: Daratumumab & Dexamethasone	4	33	5
other	Alkaline phosphatase increased	Investigations	B: Daratumumab, Dexamethasone and Lenalidomide	6	12	9
other	Alkaline phosphatase increased	Investigations	C: Daratumumab, Dexamethasone and Bortezomib	0	7	0
other	Aspartate aminotransferase increased	Investigations	A: Daratumumab & Dexamethasone	2	33	2
other	Aspartate aminotransferase increased	Investigations	B: Daratumumab, Dexamethasone and Lenalidomide	4	12	9
other	Aspartate aminotransferase increased	Investigations	C: Daratumumab, Dexamethasone and Bortezomib	1	7	2
other	Alanine aminotransferase increased	Investigations	A: Daratumumab & Dexamethasone	2	33	2
other	Alanine aminotransferase increased	Investigations	B: Daratumumab, Dexamethasone and Lenalidomide	2	12	13

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04151667/events

API reference For AI assistants

Adverse events630

Sources 3

Read this list from software.